Tissue sample preservation is a key parameter to uncovering the full genomic story in order to further personalize treatment paths. For patients with advanced solid tumor cancers, ultra-comprehensive genomic testing, like the OncoExTra® test, can help ensure that tissue samples are used efficiently.
Today’s targeted treatments demand biomarker testing
The use of biomarker testing and next-generation sequencing is a growing trend.1 Multigene genomic sequencing is also preferred by major guidelines for patients with advanced solid tumors who are eligible for an FDA-approved biomarker-linked therapy.2
of oncology medicines launched from 2015 to 2019 in the United States require or recommend testing for pharmacogenomic biomarkers1
oncologists report using next-generation sequencing to help guide treatment decisions3
of US patients with cancer miss out on precision oncology treatment because of suboptimal testing practices4
Pathologists have the expertise to offer the benefits of precision medicine by owning the tissue sample journey and ensuring efficient tissue testing. Personalized attention can make all the difference—not only for the patient's journey, but for the journey of the tumor sample as well.
Stay ahead of testing process barriers with these solutions
-
Communicate early and often across your patient’s care team
-
Be part of the initial tumor sampling
-
Prioritize the most appropriate and comprehensive tests first
Performing ultra-comprehensive genomic profiling early provides numerous benefits
For eligible patients, ordering a more comprehensive testing option early may help to:- Allow for efficient use of tumor biopsy tissue2
- Avoid degradation of tumor sample quality5,6
- Summarize comprehensive results in a single report
- Reduce delays in treatment initiation2
Make the most of every tissue sample with the OncoExTra test
The OncoExTra test uncovers the full genomic story by looking at DNA+RNA
Interrogates ~20,000 genes8
Delivers high accuracy with 98.8% sensitivity and >99.9% specificity8
Covers all DNA protein-coding sequences and all RNA transcripts8
Highlights results in an easy-to-interpret report featuring mutations associated with FDA-approved treatments and clinical trial options*
The OncoExTra test may be right for patients with advanced solid tumor cancer that is rare, aggressive, or unresponsive to treatment.
OncoExTra guidelines offer instructions tailored to your specimen type to enable a seamless preparation and shipping experience.
Actionable variants were found across many different types of solid tumors,8 including:
98% of colorectal cancer samples (164/167)
96% of lung cancer samples (53/55)
96% of bladder cancer samples (25/26)
93% of breast cancer samples (80/86)
A streamlined solution that may expedite time to treatment
- Results provided in the OncoExTra report within 14 days of receiving samples8
- Comprehensive insights may mitigate the need for additional testing
- The easy-to-interpret report facilitates shared decision-making
Get a detailed view of the results
Learn about the OncoExTra lab
Request OncoExTra specimen kits
Request at least 2 kits using the OncoExTra kit request form or by calling Customer Service at 866.662.6897. Please note that each order requires 2 samples (solid tumor tissue and matched-normal blood), which typically ship from different locations. Kit requests are usually processed within 1 business day and shipped priority overnight.
EDTA, ethylenediaminetetraacetic acid; FFPE, formalin-fixed paraffin-embedded; FISH, fluorescence in situ hybridization; H&E, hematoxylin and eosin; IHC, immunohistochemistry.
*The OncoExTra test is not an FDA-cleared or -approved IVD device or companion diagnostic for the referenced biomarkers and FDA-approved therapies.
†Retrospective analysis of 1,509 clinical reports, of which 1,261 included both DNA and RNA profiling. OncoExTra RNA findings detected variants in 5.9% [75/1,261] of samples vs 3.5% [44/1,261] in DNA analysis.8
‡Clinically actionable variants are defined as variants that are associated with available therapies or clinical trial enrollment for a specific somatic variant identified in a patient’s tumor.8
-
References